- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06317662
새로 진단된 KMT2A 재배열 백혈병 또는 KMT2A 재배열되지 않은 백혈병이 있는 유아를 위한 일반적인 화학요법 치료에 항암제 베네토클락스 및/또는 항암 면역요법인 블리나투모맙을 추가하는 방법을 테스트합니다.
KMT2A 재배열 환자에 베네토클락스 추가를 무작위 배정하여 새로 진단된 급성 림프구성 백혈병 영유아를 대상으로 블리나투모맙과 화학요법을 병용하는 2상 연구
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.
연구 개요
상태
개입 / 치료
- 의약품: Cyclophosphamide
- 의약품: Doxorubicin
- 의약품: Vincristine
- 절차: Computed Tomography
- 절차: Magnetic Resonance Imaging
- 절차: Echocardiography Test
- 절차: Multigated Acquisition Scan
- 생물학적: Blinatumomab
- 절차: Bone Marrow Aspiration
- 의약품: Daunorubicin
- 절차: Lumbar Puncture
- 의약품: Methylprednisolone
- 절차: Biospecimen Collection
- 의약품: Calaspargase Pegol
- 의약품: Therapeutic Hydrocortisone
- 의약품: Asparaginase Erwinia chrysanthemi
- 의약품: Cytarabine
- 의약품: Dexamethasone
- 절차: FDG-Positron Emission Tomography
- 의약품: Leucovorin
- 의약품: Levoleucovorin
- 의약품: Mercaptopurine
- 의약품: Methotrexate
- 의약품: Thioguanine
- 의약품: Venetoclax
- 의약품: Prednisolone
- 의약품: Prednisone
상세 설명
PRIMARY OBJECTIVES:
I. To evaluate the safety and tolerability of venetoclax in addition to a standard chemotherapy backbone and two cycles of blinatumomab in infants (aged 365 days or less at diagnosis) with newly diagnosed KMT2A-R ALL.
II. To determine in a randomized manner if the addition of venetoclax to induction chemotherapy improves end of induction minimal residual disease (MRD)-negative remission rates in infants with KMT2A-R ALL.
SECONDARY OBJECTIVES:
I. To estimate the MRD-negative remission rate for all eligible infants with KMT2A-R ALL treated with venetoclax at the recommended phase 2 dose (RP2D).
II. To compare event free survival (EFS) rates of infants with KMT2A-R ALL treated on arm B to those treated on arm A.
III. To compare 3-year EFS rates of infants with KMT2A-R ALL treated on arm A to historical controls.
IV. To determine the feasibility of treating infants with KMT2A-G ALL with a Children's Oncology Group (COG) high risk ALL chemotherapy backbone and two cycles of blinatumomab and estimate the 3-year EFS rate of infants with KMT2A-G ALL treated on arm C.
V. To characterize the pharmacokinetics (PK) of venetoclax in infants.
EXPLORATORY OBJECTIVES:
I. To describe 3-year EFS rate of infants with KMT2A-R ALL treated on arm B. II. To evaluate the use of high-throughput sequencing (HTS) for MRD detection in infant ALL compared to centralized flow cytometry.
III. To characterize the PK of calaspargase pegol in infants with ALL. IV. To report the incidence of CD19 negative relapse and myeloid switch relapse with protocol therapy.
V. To evaluate the impact of venetoclax in combination with chemotherapy on T-cell subsets and function.
VI. To describe the feasibility of T-cell collection and success of T-cell manufacturing for infants with KMT2A-R ALL who receive chimeric antigen receptor (CAR) T- cell therapy after coming off protocol therapy.
VII. To determine predictors of response and resistance to venetoclax and overall protocol therapy.
VIII. To evaluate the impact of subsequent anti-cancer therapy on overall survival after coming off protocol therapy.
IX. To compare overall survival (OS) rates of infants by arms and to historical OS rates.
OUTLINE:
STEROID PREPHASE: All patients receive prednisone or prednisolone orally (PO) or nasogastrically (NG) three times daily (TID) or methylprednisolone intravenously (IV) TID for 7 days prior to the start of induction therapy (on days 1-7).
Patients who are KMT2A gene rearrangement positive are assigned to the safety phase cohort during the safety phase of the study, or randomized between Arm A and Arm B during the expansion phase of the study. Patients who are KMT2A gene rearrangement negative are assigned to Arm C.
SAFETY PHASE COHORT (CLOSED TO ACCRUAL 06/03/2026):
INDUCTION: Patients receive venetoclax PO or NG once daily (QD) on days 1-7, 1-10, or 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy (methotrexate, hydrocortisone, cytarabine) intrathecally (IT) on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when absolute neutrophil counts (ANC) >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-central nervous system (CNS) extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine subcutaneously (SC) QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
EXPANSION PHASE: After completion of Safety phase, patients who are KMT2A gene rearrangement positive are randomized to Arm A or Arm B.
ARM A:
INDUCTION: Patients receive daunorubicin IV over 1-15 minutes on days 1 and 2, cytarabine SC or IV over 1-30 minutes on days 1-14, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29, or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
ARM B: Patients are assigned to 1 of 4 cohorts.
COHORT 1:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA + VENETOCLAX: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, venetoclax PO or NG QD on days 22-35, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
COHORT 2:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14 and 29-42, cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
COHORT 3:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14 and 29-42, cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA + VENETOCLAX: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, venetoclax PO or NG QD on days 22-35, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
COHORT 4:
INDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
MAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.
ARM C:
INDUCTION: Patients receive daunorubicin IV over 1-15 minutes on days 1 and 2, cytarabine SC or IV over 1-30 minutes on days 1-14, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29, or days 1, 8, 15, 22, and 29. Patients with < 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC >= 500/uL and platelets >= 50,000/uL. Patients with >= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.
BLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and methotrexate IT on days 15 and 29. Patients who are MRD >= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
CONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, methotrexate IT on days 8, 15, and 22, vincristine IV on days 15, 22, 43, and 50, and calaspargase pegol IV over 1-2 hours on days 15 and 43. Patients who are MRD >= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to interim maintenance 1 the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
INTERIM MAINTENANCE 1: Patients receive vincristine IV on days 1, 15, 29, and 43, high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, mercaptopurine PO or NG on days 1-14, 15-28, 29-42, and 43-56, methotrexate IT on days 1 and 29, and leucovorin PO or NG or IV or levoleucovorin IV on days 3-4, 17-18, 31-32, and 45-46. At the end of interim maintenance 1 (day 63), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC >= 500/uL and platelets >= 50,000/uL.
BLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28, and methotrexate IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
DELAYED INTENSIFICATION: Patients receive methotrexate IT on days 1, 29, and 36, dexamethasone PO, NG, or IV BID on days 1-7 and 15-21, vincristine IV on days 1, 8, 15, 43, and 50, doxorubicin IV over 3-15 minutes on days 1, 8, and 15, calaspargase pegol IV over 1-2 hours on days 4 and 43, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO or NG on days 29-42, and cytarabine SC or IV over 1-30 minutes on days 29-32 and 36-39. At the end of delayed intensification (day 63), all patients proceed directly to interim maintenance 2 the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
INTERIM MAINTENANCE 2: Patients receive vincristine IV on days 1, 11, 21, 31, and 41, methotrexate IV push over 2-5 minutes or IV over 10-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and calaspargase pegol IV over 1-2 hours on days 2 and 23. At the end of interim maintenance 2 (day 56), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC >= 750/uL and platelets >= 75,000/uL.
MAINTENANCE: Patients receive methotrexate IT on day 1 of cycles 1-3, vincristine IV on day 1 of each cycle, prednisone or prednisolone PO or NG BID or methylprednisolone IV BID on days 1-5 of each cycle, mercaptopurine PO or NG on days 1-84 of each cycle, and methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of interim maintenance 1 in the absence of disease progression or unacceptable toxicity.
All patients undergo bone marrow aspiration, collection of blood samples and echocardiography (ECHO) or multigated acquisition scan (MUGA) throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), fludeoxyglucose-positron emission tomography (FDG-PET), and/or lumbar puncture if clinically indicated.
After completion of study treatment, patients are followed up for up to 3 years.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 모병
- Children's Hospital of Alabama
-
연락하다:
- Site Public Contact
- 전화번호: 205-638-9285
- 이메일: oncologyresearch@peds.uab.edu
-
수석 연구원:
- Matthew A. Kutny
-
-
Alaska
-
Anchorage, Alaska, 미국, 99508
- 모병
- Providence Alaska Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 907-212-6871
- 이메일: AKPAMC.OncologyResearchSupport@providence.org
-
수석 연구원:
- Brenda J. Wittman
-
-
Arizona
-
Mesa, Arizona, 미국, 85202
- 모병
- Banner Children's at Desert
-
연락하다:
- Site Public Contact
- 전화번호: 480-412-3100
-
수석 연구원:
- Joseph C. Torkildson
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72202-3591
- 모병
- Arkansas Children's Hospital
-
수석 연구원:
- Michael W. Bishop
-
연락하다:
- Site Public Contact
- 전화번호: 501-364-7373
-
-
California
-
Loma Linda, California, 미국, 92354
- 모병
- Loma Linda University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 909-558-4050
-
수석 연구원:
- Albert Kheradpour
-
Long Beach, California, 미국, 90806
- 모병
- Miller Children's and Women's Hospital Long Beach
-
연락하다:
- Site Public Contact
- 전화번호: 562-933-5600
-
수석 연구원:
- Jacqueline N. Casillas
-
Oakland, California, 미국, 94611
- 모병
- Kaiser Permanente-Oakland
-
연락하다:
- Site Public Contact
- 전화번호: 877-642-4691
- 이메일: Kpoct@kp.org
-
수석 연구원:
- Aarati V. Rao
-
Oakland, California, 미국, 94609
- 모병
- UCSF Benioff Children's Hospital Oakland
-
수석 연구원:
- Anya Levinson
-
연락하다:
- Site Public Contact
- 전화번호: 510-428-3264
- 이메일: PedOncRschOAK@ucsf.edu
-
Orange, California, 미국, 92868
- 모병
- Children's Hospital of Orange County
-
연락하다:
- Site Public Contact
- 전화번호: 714-509-8646
- 이메일: oncresearch@choc.org
-
수석 연구원:
- Elyssa M. Rubin
-
Sacramento, California, 미국, 95817
- 모병
- University of California Davis Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 916-734-3089
-
수석 연구원:
- Marcio H. Malogolowkin
-
San Francisco, California, 미국, 94158
- 모병
- UCSF Medical Center-Mission Bay
-
수석 연구원:
- Anya Levinson
-
연락하다:
- Site Public Contact
- 전화번호: 877-827-3222
- 이메일: cancertrials@ucsf.edu
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
수석 연구원:
- Kelly E. Faulk
-
연락하다:
- Site Public Contact
- 전화번호: 303-764-5056
- 이메일: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- 모병
- Connecticut Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 860-545-9981
-
수석 연구원:
- Michael S. Isakoff
-
New Haven, Connecticut, 미국, 06520
- 모병
- Yale University
-
연락하다:
- Site Public Contact
- 전화번호: 203-785-5702
- 이메일: canceranswers@yale.edu
-
수석 연구원:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, 미국, 19803
- 모병
- Alfred I duPont Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Emi H. Caywood
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Children's National Medical Center
-
수석 연구원:
- Jeffrey S. Dome
-
연락하다:
- Site Public Contact
- 전화번호: 202-476-2800
- 이메일: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville, Florida, 미국, 32610
- 모병
- UF Health Cancer Institute - Gainesville
-
수석 연구원:
- Brian Stover
-
연락하다:
- Site Public Contact
- 전화번호: 352-273-8010
-
Hollywood, Florida, 미국, 33021
- 모병
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 954-265-1847
- 이메일: OHR@mhs.net
-
수석 연구원:
- Iftikhar Hanif
-
Jacksonville, Florida, 미국, 32207
- 모병
- Nemours Children's Clinic-Jacksonville
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Emi H. Caywood
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 305-243-2647
-
수석 연구원:
- Julio C. Barredo
-
Orlando, Florida, 미국, 32806
- 모병
- Arnold Palmer Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 321-841-5357
- 이메일: Jennifer.spinelli@orlandohealth.com
-
수석 연구원:
- Zhongbo Hu
-
Orlando, Florida, 미국, 32827
- 모병
- Nemours Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Emi H. Caywood
-
Orlando, Florida, 미국, 32803
- 모병
- AdventHealth Orlando
-
연락하다:
- Site Public Contact
- 전화번호: 407-303-2090
- 이메일: FH.Cancer.Research@flhosp.org
-
수석 연구원:
- Fouad M. Hajjar
-
Pensacola, Florida, 미국, 32504
- 모병
- Nemours Children's Clinic - Pensacola
-
연락하다:
- Site Public Contact
- 이메일: helpdesk@childrensoncologygroup.org
-
수석 연구원:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, 미국, 33701
- 모병
- Johns Hopkins All Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 727-767-4784
- 이메일: Ashley.Repp@jhmi.edu
-
수석 연구원:
- Jennifer B. Dean
-
Tampa, Florida, 미국, 33607
- 모병
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
연락하다:
- Site Public Contact
- 전화번호: 813-357-0849
- 이메일: jennifer.manns@baycare.org
-
수석 연구원:
- Don E. Eslin
-
West Palm Beach, Florida, 미국, 33407
- 모병
- Saint Mary's Medical Center
-
수석 연구원:
- Matthew D. Ramirez
-
연락하다:
- Site Public Contact
- 전화번호: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
수석 연구원:
- Melinda G. Pauly
-
연락하다:
- Site Public Contact
- 전화번호: 404-785-0232
- 이메일: Olivia.Floyd@choa.org
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96826
- 모병
- Kapiolani Medical Center for Women and Children
-
연락하다:
- Site Public Contact
- 전화번호: 808-983-6090
-
수석 연구원:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, 미국, 83712
- 모병
- Saint Luke's Cancer Institute - Boise
-
수석 연구원:
- Martha M. Pacheco
-
연락하다:
- Site Public Contact
- 전화번호: 208-381-2774
- 이메일: eslinget@slhs.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Lurie Children's Hospital-Chicago
-
연락하다:
- Site Public Contact
- 전화번호: 773-880-4562
-
수석 연구원:
- Sara Zarnegar-Lumley
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 773-702-8222
- 이메일: cancerclinicaltrials@bsd.uchicago.edu
-
수석 연구원:
- Gabrielle Lapping-Carr
-
Oak Lawn, Illinois, 미국, 60453
- 모병
- Advocate Children's Hospital-Oak Lawn
-
연락하다:
- Site Public Contact
- 전화번호: 847-723-7570
-
수석 연구원:
- Rebecca E. McFall
-
Park Ridge, Illinois, 미국, 60068
- 모병
- Advocate Children's Hospital-Park Ridge
-
연락하다:
- Site Public Contact
- 이메일: helpdesk@childrensoncologygroup.org
-
수석 연구원:
- Rebecca E. McFall
-
Peoria, Illinois, 미국, 61637
- 모병
- OSF Children's Hospital of Illinois
-
수석 연구원:
- Prerna Kumar
-
연락하다:
- Site Public Contact
- 전화번호: 309-624-4945
- 이메일: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, 미국, 62702
- 모병
- Southern Illinois University School of Medicine
-
연락하다:
- Site Public Contact
- 전화번호: 217-545-7929
-
수석 연구원:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Riley Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 800-248-1199
-
수석 연구원:
- Amanda Saraf
-
Indianapolis, Indiana, 미국, 46260
- 모병
- Ascension Saint Vincent Indianapolis Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 317-338-2194
- 이메일: research@stvincent.org
-
수석 연구원:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, 미국, 50309
- 모병
- Blank Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 515-241-8912
- 이메일: samantha.mallory@unitypoint.org
-
수석 연구원:
- Samantha L. Mallory
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 모병
- University of Kentucky/Markey Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 859-257-3379
-
수석 연구원:
- James T. Badgett
-
Louisville, Kentucky, 미국, 40202
- 모병
- Norton Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 502-629-5500
- 이메일: CancerResource@nortonhealthcare.org
-
수석 연구원:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70118
- 모병
- Children's Hospital New Orleans
-
수석 연구원:
- Maria C. Velez-Yanguas
-
연락하다:
- Site Public Contact
- 전화번호: 504-894-5377
-
New Orleans, Louisiana, 미국, 70121
- 모병
- Ochsner Medical Center Jefferson
-
연락하다:
- Site Public Contact
- 전화번호: 504-842-8084
- 이메일: Elisemarie.curry@ochsner.org
-
수석 연구원:
- Craig Lotterman
-
-
Maine
-
Scarborough, Maine, 미국, 04074
- 모병
- Maine Children's Cancer Program
-
수석 연구원:
- Sei-Gyung K. Sze
-
연락하다:
- Site Public Contact
- 전화번호: 207-396-8670
- 이메일: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
수석 연구원:
- Stacy L. Cooper
-
연락하다:
- Site Public Contact
- 전화번호: 410-955-8804
- 이메일: jhcccro@jhmi.edu
-
Baltimore, Maryland, 미국, 21215
- 모병
- Sinai Hospital of Baltimore
-
수석 연구원:
- Jason M. Fixler
-
연락하다:
- Site Public Contact
- 전화번호: 410-601-9083
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute
-
수석 연구원:
- Melissa A. Burns
-
연락하다:
- Site Public Contact
- 전화번호: 877-442-3324
-
Worcester, Massachusetts, 미국, 01655
- 모병
- UMass Memorial Medical Center - University Campus
-
연락하다:
- Site Public Contact
- 전화번호: 508-856-3216
- 이메일: cancer.research@umassmed.edu
-
수석 연구원:
- Stefanie R. Lowas
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- C S Mott Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-865-1125
-
수석 연구원:
- Joshua W. Goldman
-
Grand Rapids, Michigan, 미국, 49503
- 모병
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, 미국, 49007
- 모병
- Bronson Methodist Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen Y. Butler
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- University of Minnesota/Masonic Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 612-624-2620
-
수석 연구원:
- Peter M. Gordon
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- 모병
- University of Mississippi Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 601-815-6700
-
수석 연구원:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- 모병
- Children's Mercy Hospitals and Clinics
-
수석 연구원:
- Keith J. August
-
연락하다:
- Site Public Contact
- 전화번호: 816-302-6808
- 이메일: COGResearchGroup@cmh.edu
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Laura G. Schuettpelz
-
St Louis, Missouri, 미국, 63141
- 모병
- Mercy Hospital Saint Louis
-
연락하다:
- Site Public Contact
- 전화번호: 314-251-7066
-
수석 연구원:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68114
- 모병
- Children's Hospital and Medical Center of Omaha
-
연락하다:
- Site Public Contact
- 전화번호: 402-955-3949
-
수석 연구원:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89135
- 모병
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
연락하다:
- Site Public Contact
- 전화번호: 702-384-0013
- 이메일: research@sncrf.org
-
수석 연구원:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- 모병
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
수석 연구원:
- Angela Ricci
-
연락하다:
- Site Public Contact
- 전화번호: 800-639-6918
- 이메일: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모병
- Hackensack University Medical Center
-
수석 연구원:
- Jing Chen
-
연락하다:
- Site Public Contact
- 전화번호: 551-996-2897
-
Morristown, New Jersey, 미국, 07960
- 모병
- Morristown Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-971-5900
-
수석 연구원:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
수석 연구원:
- Marissa Botwinick
-
연락하다:
- Site Public Contact
- 전화번호: 732-235-8675
-
Paterson, New Jersey, 미국, 07503
- 모병
- Saint Joseph's Regional Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-754-2207
- 이메일: HallL@sjhmc.org
-
수석 연구원:
- Alissa Kahn
-
-
New York
-
Albany, New York, 미국, 12208
- 모병
- Albany Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 518-262-5513
-
수석 연구원:
- Lauren R. Weintraub
-
Buffalo, New York, 미국, 14263
- 모병
- Roswell Park Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 800-767-9355
- 이메일: askroswell@roswellpark.org
-
수석 연구원:
- Lisa Niswander
-
New Hyde Park, New York, 미국, 11040
- 모병
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
연락하다:
- Site Public Contact
- 전화번호: 718-470-3460
-
수석 연구원:
- Julie I. Krystal
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 212-639-7592
-
수석 연구원:
- Kavitha Ramaswamy
-
New York, New York, 미국, 10016
- 모병
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
수석 연구원:
- Elizabeth A. Raetz
-
연락하다:
- Site Public Contact
- 이메일: CancerTrials@nyulangone.org
-
New York, New York, 미국, 10065
- 모병
- NYP/Weill Cornell Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 212-746-1848
-
수석 연구원:
- Jaclyn Rosenzweig
-
Rochester, New York, 미국, 14642
- 모병
- University of Rochester
-
연락하다:
- Site Public Contact
- 전화번호: 585-275-5830
-
수석 연구원:
- Carol Fries Simpson
-
Syracuse, New York, 미국, 13210
- 모병
- State University of New York Upstate Medical University
-
연락하다:
- Site Public Contact
- 전화번호: 315-464-5476
-
수석 연구원:
- Melanie A. Comito
-
The Bronx, New York, 미국, 10467
- 모병
- Montefiore Medical Center - Moses Campus
-
연락하다:
- Site Public Contact
- 전화번호: 718-379-6866
- 이메일: eskwak@montefiore.org
-
수석 연구원:
- Alice Lee
-
Valhalla, New York, 미국, 10595
- 모병
- New York Medical College
-
연락하다:
- Site Public Contact
- 전화번호: 914-594-3794
-
수석 연구원:
- Andrew J. Bellantoni
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- UNC Lineberger Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 877-668-0683
- 이메일: cancerclinicaltrials@med.unc.edu
-
수석 연구원:
- Thomas B. Alexander
-
Charlotte, North Carolina, 미국, 28203
- 모병
- Carolinas Medical Center/Levine Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 800-804-9376
-
수석 연구원:
- Joel A. Kaplan
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
수석 연구원:
- Jessica M. Sun
-
연락하다:
- Site Public Contact
- 전화번호: 888-275-3853
-
Greenville, North Carolina, 미국, 27834
- 모병
- East Carolina University
-
연락하다:
- Site Public Contact
- 전화번호: 252-744-1015
- 이메일: eubankss@ecu.edu
-
수석 연구원:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Wake Forest University Health Sciences
-
연락하다:
- Site Public Contact
- 전화번호: 336-713-6771
-
수석 연구원:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58122
- 모병
- Sanford Broadway Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 701-323-5760
- 이메일: OncologyClinicalTrialsFargo@sanfordhealth.org
-
수석 연구원:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, 미국, 44308
- 모병
- Children's Hospital Medical Center of Akron
-
연락하다:
- Site Public Contact
- 전화번호: 330-543-3193
-
수석 연구원:
- Lauren R. Draper
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 513-636-2799
- 이메일: cancer@cchmc.org
-
수석 연구원:
- Erin H. Breese
-
Cleveland, Ohio, 미국, 44106
- 모병
- Rainbow Babies and Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 216-844-5437
-
수석 연구원:
- Duncan S. Stearns
-
Dayton, Ohio, 미국, 45404
- 모병
- Dayton Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-228-4055
-
수석 연구원:
- Jordan M. Wright
-
Toledo, Ohio, 미국, 43606
- 모병
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 419-824-1842
- 이메일: PCIOncResearch@promedica.org
-
수석 연구원:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma Health Sciences Center
-
연락하다:
- Site Public Contact
- 전화번호: 405-271-8777
- 이메일: ou-clinical-trials@ouhsc.edu
-
수석 연구원:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- 모병
- Lehigh Valley Hospital-Cedar Crest
-
연락하다:
- Site Public Contact
- 전화번호: 610-402-9543
- 이메일: Morgan_M.Horton@lvhn.org
-
수석 연구원:
- Jacob A. Troutman
-
Danville, Pennsylvania, 미국, 17822
- 모병
- Geisinger Medical Center
-
수석 연구원:
- Jagadeesh Ramdas
-
연락하다:
- Site Public Contact
- 전화번호: 570-271-5251
- 이메일: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Penn State Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 717-531-6012
-
수석 연구원:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
연락하다:
- Site Public Contact
- 전화번호: 267-425-5544
- 이메일: CancerTrials@email.chop.edu
-
수석 연구원:
- Kathrin M. Bernt
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- Children's Hospital of Pittsburgh of UPMC
-
연락하다:
- Site Public Contact
- 전화번호: 412-692-8570
- 이메일: jean.tersak@chp.edu
-
수석 연구원:
- Jenny Ruiz
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02903
- 모병
- Rhode Island Hospital
-
수석 연구원:
- Bradley DeNardo
-
연락하다:
- Site Public Contact
- 전화번호: 401-444-1488
-
-
South Carolina
-
Columbia, South Carolina, 미국, 29203
- 모병
- Prisma Health Richland Hospital
-
수석 연구원:
- Stuart L. Cramer
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, 미국, 29605
- 모병
- BI-LO Charities Children's Cancer Center
-
수석 연구원:
- Aniket Saha
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57117-5134
- 모병
- Sanford USD Medical Center - Sioux Falls
-
연락하다:
- Site Public Contact
- 전화번호: 605-312-3320
- 이메일: OncologyClinicalTrialsSF@SanfordHealth.org
-
수석 연구원:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37916
- 모병
- East Tennessee Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 865-541-8266
-
수석 연구원:
- Susan E. Spiller
-
Memphis, Tennessee, 미국, 38105
- 모병
- Saint Jude Children's Research Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 888-226-4343
- 이메일: referralinfo@stjude.org
-
수석 연구원:
- Matthew Rees
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University/Ingram Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-811-8480
-
수석 연구원:
- Brianna N. Smith
-
Nashville, Tennessee, 미국, 37203
- 모병
- The Children's Hospital at TriStar Centennial
-
연락하다:
- Site Public Contact
- 전화번호: 615-342-1919
-
수석 연구원:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, 미국, 78723
- 모병
- Dell Children's Medical Center of Central Texas
-
연락하다:
- Site Public Contact
- 전화번호: 512-628-1902
- 이메일: TXAUS-DL-SFCHemonc.research@ascension.org
-
수석 연구원:
- Shannon M. Cohn
-
Corpus Christi, Texas, 미국, 78411
- 모병
- Driscoll Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 361-694-5311
- 이메일: Crystal.DeLosSantos@dchstx.org
-
수석 연구원:
- Nkechi I. Mba
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern/Simmons Cancer Center-Dallas
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
수석 연구원:
- Caroline Smith
-
Dallas, Texas, 미국, 75230
- 모병
- Medical City Dallas Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 972-566-5588
-
수석 연구원:
- Maurizio L. Ghisoli
-
El Paso, Texas, 미국, 79905
- 모병
- El Paso Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 915-298-5444
- 이메일: ranjan.bista@ttuhsc.edu
-
수석 연구원:
- Benjamin Carcamo
-
Fort Worth, Texas, 미국, 76104
- 모병
- Cook Children's Medical Center
-
수석 연구원:
- Holly Pacenta
-
연락하다:
- Site Public Contact
- 전화번호: 682-885-2103
- 이메일: CookChildrensResearch@cookchildrens.org
-
Houston, Texas, 미국, 77030
- 모병
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
수석 연구원:
- Joanna S. Yi
-
연락하다:
- Site Public Contact
- 전화번호: 713-798-1354
- 이메일: burton@bcm.edu
-
San Antonio, Texas, 미국, 78207
- 모병
- Children's Hospital of San Antonio
-
연락하다:
- Site Public Contact
- 전화번호: 210-704-2894
- 이메일: bridget.medina@christushealth.org
-
수석 연구원:
- Julie Voeller
-
San Antonio, Texas, 미국, 78229
- 모병
- Methodist Children's Hospital of South Texas
-
연락하다:
- Site Public Contact
- 전화번호: 210-575-6240
- 이메일: Vinod.GidvaniDiaz@hcahealthcare.com
-
수석 연구원:
- Jose M. Esquilin
-
Temple, Texas, 미국, 76508
- 모병
- Scott and White Memorial Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 254-724-5407
-
수석 연구원:
- Nicholas W. McGregor
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22908
- 모병
- University of Virginia Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 434-243-6303
- 이메일: uvacancertrials@hscmail.mcc.virginia.edu
-
수석 연구원:
- Brian C. Belyea
-
Norfolk, Virginia, 미국, 23507
- 모병
- Children's Hospital of The King's Daughters
-
연락하다:
- Site Public Contact
- 전화번호: 757-668-7243
- 이메일: CCBDCresearch@chkd.org
-
수석 연구원:
- Melissa S. Mark
-
Richmond, Virginia, 미국, 23298
- 모병
- VCU Massey Comprehensive Cancer Center
-
수석 연구원:
- Jordyn R. Griffin
-
연락하다:
- Site Public Contact
- 전화번호: 804-628-6430
- 이메일: CTOclinops@vcu.edu
-
Roanoke, Virginia, 미국, 24014
- 모병
- Carilion Children's
-
연락하다:
- Site Public Contact
- 전화번호: 540-266-6238
- 이메일: wpmccarty@carilionclinic.org
-
수석 연구원:
- Erwood G. Edwards
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 866-987-2000
-
수석 연구원:
- Sarah E. Leary
-
Spokane, Washington, 미국, 99204
- 모병
- Providence Sacred Heart Medical Center and Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-228-6618
- 이메일: HopeBeginsHere@providence.org
-
수석 연구원:
- Judy L. Felgenhauer
-
-
Wisconsin
-
Green Bay, Wisconsin, 미국, 54301
- 모병
- Saint Vincent Hospital Cancer Center Green Bay
-
수석 연구원:
- Catherine A. Long
-
연락하다:
- Site Public Contact
- 전화번호: 920-433-8889
- 이메일: WI_research_admin@hshs.org
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- Children's Hospital of Wisconsin
-
연락하다:
- Site Public Contact
- 전화번호: 414-955-4727
- 이메일: MACCCTO@mcw.edu
-
수석 연구원:
- Zachary Graff
-
-
-
-
-
San Juan, 푸에르토 리코, 00926
- 모병
- University Pediatric Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 787-474-0333
-
수석 연구원:
- Maria E. Echevarria
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
All patients must be enrolled on APEC14B1 and consented to eligibility screening (part A) prior to treatment and enrollment on AALL2321
-
Infants (aged 365 days or less) on the date of diagnosis are eligible; infants must be > 36 weeks gestational age (cumulative prenatal and postnatal age must be > 36 weeks) at the time of enrollment
-
Patients must have newly diagnosed B-acute lymphoblastic leukemia (B-ALL, 2017 World Health Organization [WHO] classification), also termed B-precursor ALL, or acute leukemia of ambiguous lineage (ALAL), which includes mixed phenotype acute leukemia. For patients with ALAL, the immunophenotype of the leukemia must comprise at least 50% B lineage
- Diagnostic immunophenotype: Leukemia cells must express CD19
Exclusion Criteria:
-
Patients with Down Syndrome
-
Patients with secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy
-
Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of infant ALL or for any cancer diagnosis prior to the initiation of protocol therapy, with the exception of:
-
Steroid pretreatment:
- PredniSONE, prednisoLONE, or methylPREDNISolone for ≤ 72 hours (3 days) in the 7 days prior to enrollment. The dose of predniSONE, prednisoLONE or methylPREDNISolone does not affect eligibility
- Inhaled and topical steroids are not considered pretreatment
- Note: Pretreatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone used during or within 6 hours prior to or after sedation to prevent or treat airway edema. However, prior exposure to ANY steroids that occurred > 28 days before enrollment does not affect eligibility
-
Intrathecal cytarabine or methotrexate:
- An intrathecal dose of cytarabine or methotrexate in the 7 days prior to enrollment does not affect eligibility
- Note: The preference is to defer the diagnostic lumbar puncture with intrathecal chemotherapy to day 1 of induction to allow for cytoreduction of circulating blasts and decrease the potential for central nervous system (CNS) contamination due to a traumatic tap. If done prior to day 1 of induction, these results will be used to determine CNS status
-
Hydroxyurea:
- Pretreatment with ≤ 72 hours (3 days) of hydroxyurea in the 7 days prior to enrollment does not affect eligibility
-
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA) and National Cancer Institute (NCI) requirements for human studies must be met
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Arm A
See Detailed Description for Arm A. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo lumbar puncture
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Given IV
다른 이름들:
Given IT
다른 이름들:
Given recombinant crisantaspase IM or crisantaspase IM or IV
다른 이름들:
Given IT or IV
다른 이름들:
Given PO or NG or IV
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or NG
다른 이름들:
Given IT or IV or PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
|
실험적: Arm B, Cohort 1
See Detailed Description for Arm B, Cohort 1. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo lumbar puncture
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Given IV
다른 이름들:
Given IT
다른 이름들:
Given recombinant crisantaspase IM or crisantaspase IM or IV
다른 이름들:
Given IT or IV
다른 이름들:
Given PO or NG or IV
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or NG
다른 이름들:
Given IT or IV or PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
|
실험적: Arm B, Cohort 2
See Detailed Description for Arm B, Cohort 2. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo lumbar puncture
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Given IV
다른 이름들:
Given IT
다른 이름들:
Given recombinant crisantaspase IM or crisantaspase IM or IV
다른 이름들:
Given IT or IV
다른 이름들:
Given PO or NG or IV
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or NG
다른 이름들:
Given IT or IV or PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
|
실험적: Arm B, Cohort 3
See Detailed Description for Arm B, Cohort 3. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo lumbar puncture
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Given IV
다른 이름들:
Given IT
다른 이름들:
Given recombinant crisantaspase IM or crisantaspase IM or IV
다른 이름들:
Given IT or IV
다른 이름들:
Given PO or NG or IV
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or NG
다른 이름들:
Given IT or IV or PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
|
실험적: Arm B, Cohort 4
See Detailed Description for Arm B, Cohort 4. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo lumbar puncture
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Given IV
다른 이름들:
Given IT
다른 이름들:
Given recombinant crisantaspase IM or crisantaspase IM or IV
다른 이름들:
Given IT or IV
다른 이름들:
Given PO or NG or IV
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or NG
다른 이름들:
Given IT or IV or PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
|
실험적: Arm C
See Detailed Description for Arm C. |
Given IV
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo lumbar puncture
다른 이름들:
Given IV
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Given IV
다른 이름들:
Given IT
다른 이름들:
Given IT or IV
다른 이름들:
Given PO or NG or IV
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or NG
다른 이름들:
Given IT or IV or PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
|
실험적: Safety Phase Cohort
See Detailed Description for Safety Phase Cohort. (CLOSED TO ACCRUAL 06/03/2026) |
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Given IV
다른 이름들:
Undergo lumbar puncture
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Given IV
다른 이름들:
Given IT
다른 이름들:
Given recombinant crisantaspase IM or crisantaspase IM or IV
다른 이름들:
Given IT or IV
다른 이름들:
Given PO or NG or IV
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or NG
다른 이름들:
Given IT or IV or PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
|
실험적: Steroid Prephase(prednisone, prednisolone, methylprednisolone)
All patients receive prednisone or prednisolone PO or NG TID or methylprednisolone IV TID for 7 days prior to the start of induction therapy (on days 1-7). |
Undergo CT
다른 이름들:
Undergo MRI
다른 이름들:
Undergo ECHO
다른 이름들:
Undergo MUGA
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given IV
다른 이름들:
Undergo collection of blood samples
다른 이름들:
Undergo FDG-PET
다른 이름들:
Given PO or NG
다른 이름들:
Given PO or NG
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of dose-limiting toxicities (DLTs) (safety phase)
기간: For the duration of the induction + venetoclax cycle
|
For the safety phase, DLTs of the induction + venetoclax cycle of KMT2A-rearranged (R) patients will be assessed. |
For the duration of the induction + venetoclax cycle
|
|
Incidence of DLTs (expansion phase)
기간: During the induction, consolidation, and MARMA cycles of Arm B
|
For the expansion phase, DLTs of Arm B will be assessed and monitored for the cycles that contain venetoclax (induction, consolidation, and MARMA cycles of Arm B). |
During the induction, consolidation, and MARMA cycles of Arm B
|
|
Minimal residual disease (MRD)-negative remission rate
기간: At the end of induction
|
The end of induction MRD-negative remission rate will be compared between Arm A and Arm B. MRD negativity is defined as achievement of complete remission and MRD < 0.01% by flow cytometry. The MRD-negative remission rate at the end of induction between Arm A and Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.15. |
At the end of induction
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
MRD-negative remission rate
기간: At the end of induction
|
MRD-negative remission rate at the end of induction and the standard error or 95% confidence interval will be estimated among infants with KMT2A-R acute lymphoblastic leukemia (ALL) treated with venetoclax at the RP2D. This analysis will include eligible KMT2A-R patients treated with venetoclax at the RP2D in the safety phase, as well as patients randomized to Arm B and treated with venetoclax in the expansion phase. MRD negativity is defined as < 0.01% by flow cytometry. |
At the end of induction
|
|
Event free survival (EFS) rates of infants with KMT2A-R ALL
기간: From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
The EFS rates from date of randomization of Arm B will be compared to Arm A. Comparison of EFS rates between Arm A and Arm B will be based on a one-sided logrank test with Type I error of 0.15. In addition, EFS rates will be estimated using the Kaplan-Meier method with Greenwood standard errors. Hazard ratios and confidence intervals will be estimated based on Cox regression models as appropriate. Cumulative incidence rates of each EFS event type (relapse, treatment failure, secondary malignant neoplasm and death) will also be estimated and presented with cumulative incidence curves and compared between arms as appropriate. |
From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
3-year EFS of infants with KMT2A-R ALL
기간: From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
For Arm A, the 3-year EFS rate (representing a plateau rate based on the shape of EFS curves of historical data in this patient population) from the date of randomization will be compared to the stable historical 3-year EFS rate of 35% observed in AALL0631 and other international trials. |
From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
Proportion of KMT2A-germline (G) patients in Arm C who are able to receive all treatment cycles before maintenance
기간: Up to interim maintenance 2
|
The feasibility of treating KMT2A-G patients with a high-risk ALL backbone and two cycles of blinatumomab (Arm C) will be assessed. Arm C treatment will be considered feasible for KMT2A-G patients if the proportion of KMT2A-G patients in Arm C who are able to receive all treatment cycles before maintenance (i.e., up to interim maintenance 2) is more than 76.8%. The proportion of patients receiving all cycles before Maintenance will be compared to 76.8% with a one-sample exact test of proportion with Type I error of 0.15. |
Up to interim maintenance 2
|
|
3-year EFS of infants with KMT2A-G ALL treated on Arm C
기간: From date of enrollment to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
The 3-year EFS rate from date of enrollment of KMT2A-G patients in Arm C will be estimated with the Kaplan-Meier method. |
From date of enrollment to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
Pharmacokinetics (PK) of venetoclax in infants
기간: On days 7, 10, and 14 of induction
|
PK samples will be collected from patients enrolled in the safety phase of the study as well as from patients randomized to Arm B in the expansion phase who consent to participate, to determine the major secondary objective of characterizing the PK of venetoclax in infants. PK samples will be evaluated in batches and standard nonlinear mixed effect modeling will be used for model building and refinement of time-concentration data. After model refinement, a non-parametric bootstrap analysis will be performed reporting the 95% confidence intervals for each PK parameter. |
On days 7, 10, and 14 of induction
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
3-year EFS of infants with KMT2A-R ALL treated on Arm B
기간: From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
Arm B, the 3-year EFS rate from date of randomization will be estimated, and will be compared to Arm A as described in the secondary objective, and to historical 3-year EFS. Comparison to historical rate will be based on a one-sample test of proportion with one-sided Type I error of 0.15. |
From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years
|
|
Use of high-throughput sequencing (HTS) for MRD detection in infant ALL compared to centralized flow cytometry
기간: Up to 3 years
|
Pre-treatment HTS clonality and HTS MRD tracking results will be collected and compared to the required centralized flow cytometry-based MRD data to evaluate the feasibility and prognostic utility of HTS MRD evaluation in the infant ALL population. |
Up to 3 years
|
|
PK of calaspargase pegol in infants with ALL
기간: At completion of the trial, up to 3 years
|
PK of calaspargase pegol will be analyzed by monitoring asparaginase activity levels. Once a PK model is developed for calaspargase pegol, standard regression analysis will be used to describe the relationship between drug exposure and asparaginase activity. Additionally, asparaginase-associated toxicities will be described for the entire study population and correlated with activity levels when possible. The result of this analysis will be an estimation of potential optimal exposure expected to yield the maximum efficacy while limiting toxicity. These analyses will be exploratory and descriptive. |
At completion of the trial, up to 3 years
|
|
Incidence of CD19-negative relapse and myeloid switch relapse with protocol therapy
기간: At the time of relapse, up to 3 years
|
For patients who experience relapse, will collect information regarding the immunophenotype of the leukemic blasts at time of relapse. Will report on the rate of CD19 negative relapse as well as myeloid switch relapse for all patients enrolled on study. This analysis will be exploratory and descriptive. |
At the time of relapse, up to 3 years
|
|
Impact of venetoclax in combination with chemotherapy on T-cell subsets and function
기간: Prior to and following the first course of venetoclax
|
BCL-2 inhibition is reported to alter T-cell subsets, including increased activation, enhanced cytotoxicity against leukemia cells and heightened resistance to cell death. Peripheral blood and bone marrow samples will be collected prior to and following the first course of venetoclax to evaluate effects on T-cell subsets and function following venetoclax exposure. |
Prior to and following the first course of venetoclax
|
|
Feasibility of T-cell collection and success of T-cell manufacturing for infants with KMT2A-R ALL who receive chimeric antigen receptor (CAR) T-cell therapy
기간: After coming off protocol therapy
|
For patients that undergo T-cell collection, will collect data regarding the feasibility of T-cell collection in the context of protocol therapy. Additionally, for patients who proceed with CAR T-cell therapy after coming off protocol therapy, will collect data regarding the success of T-cell manufacturing, infusion and response to therapy in this young population, as the success of this subsequent therapy may be heavily impacted by the effect of protocol therapy on T-cell function. These analyses will be exploratory and descriptive. |
After coming off protocol therapy
|
|
Predictors of response and resistance to venetoclax and overall protocol therapy
기간: Before and after venetoclax exposure, up to 3 years
|
Will study the inter- and intra- patient variability in the expression of apoptotic proteins (e.g., BCL-2, MCL-1, BCL-XL) and apoptotic priming at diagnosis and identify changes that occur during induction therapy in relationship to venetoclax exposure. Will then determine whether the state of BCL-2 specific apoptotic priming correlates with outcome. Will also integrate genomic and molecular features (such as developmental state, signaling, epigenomic, transcriptomic, proteomic and metabolomic states) before and after venetoclax exposure, for those assays where this type of analysis is feasible, to determine biomarkers of response and resistance to therapy for infants with ALL. |
Before and after venetoclax exposure, up to 3 years
|
|
Impact of subsequent anti-cancer therapy on overall survival
기간: After coming off protocol therapy
|
For all patients who remain in study follow-up after coming off protocol therapy, data will be collected regarding subsequent cancer directed therapies received as well as relapse and survival status in order to evaluate the impact of subsequent cancer directed therapy on the overall survival of patients enrolled on this study. These analyses will be exploratory and descriptive. |
After coming off protocol therapy
|
|
Overall survival (OS) rates
기간: From randomization to death due to any cause, up to 3 years
|
Will compare OS rates of infants by arms and to historical OS rates. The OS rates from the date of randomization of patients with KMT2A-R ALL will be compared between Arm A and Arm B. Comparison of OS rates between Arm A and Arm B will be based on a one-sided logrank test with Type I error of 0.15. In addition, OS rates of KMT2A-R patients in Arm A and Arm B will be compared to historical rates observed in similar patients in completed studies such as AALL0631 or AALL15P1. In addition, OS from enrollment of KMT2A-G patients will be compared to historical rates. OS rates will be estimated using the Kaplan-Meier method with Greenwood standard errors. Hazard ratios and confidence intervals will be estimated based on Cox regression models as appropriate. These analyses will be largely exploratory. |
From randomization to death due to any cause, up to 3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Erin H Breese, Children's Oncology Group
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 면역계 질환
- 감염
- 바이러스 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- DNA 바이러스 감염
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종, 비호지킨
- 림프종, B세포
- 림프종
- 백혈병, 림프
- 백혈병
- 엡스타인-바 바이러스 감염
- 헤르페스바이러스과 감염
- 종양 바이러스 감염
- 헴 및 림프병
- 버킷 림프종
- 백혈병, 양성 표현형, 급성
- 호르몬
- 호르몬, 호르몬 대체제, 호르몬 길항제
- 황 화합물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 구멍
- 수술 절차, 수술
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 생검
- 탄화수소
- 탄화수소, 순환
- 탄수화물
- 알칼로이드
- 다 환식 방향족 탄화수소
- 탄화수소, 방향족
- 다 환식 화합물
- 글리코 사이드
- 가수 분해 효소
- 효소
- 효소 및 코엔자임
- 인돌
- 퓨린
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 스테로이드, 불소
- 벤젠 유도체
- 화학 기술, 분석
- 설 폰산
- 황산
- 스펙트럼 분석
- 포스 포 아미드 머스타드
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 포스 포 아미드
- 유기 인 화합물
- 뉴 클레오 시드
- Formyltetrahydrofolates
- 테트라 하이드로 폴 레이트
- 엽산
- Pterins
- Teridines
- Pregnadienetriols
- Pregnadienediols
- 아미도 하이드로 라제
- Vinca 알칼로이드
- Secologanin Tryptamine 알칼로이드
- 인돌 알칼로이드
- 인돌리 지딘
- 인도인
- 아라비노 뉴 클레오 시드
- 아미노 테린
- 안트라 사이클린
- 나프 타센
- 아미노 글리코 시드
- 코엔자임
- 임신 한
- 임신
- 11- 하이드 록시 코르티코 스테로이드
- 히드 록시 코르티코 스테로이드
- 부신 피질 호르몬
- 17- 하이드 록시 코르티코 스테로이드
- 진단 기술, 신경계
- 벤젠 설포 네이트
- 아릴 설포 네이트
- 아릴 설 폰산
- 설페이드릴 화합물
- 덱사메타손
- 메토트렉세이트
- 프레드니손
- 프레드니솔론
- 시클로포스파미드
- 시타라빈
- 류코보린
- 레보류코보린
- 독소루비신
- 빈크리스틴
- 메틸프레드니솔론
- 다우노루비신
- 하이드로코르티손
- 아스파라기나제
- 메르캅토퓨린
- 티오구아닌
- 칼슘 도베실레이트
- 시편 처리
- 자기 공명 분광법
- Venetoclax
- 블리나투모 맙
- 척추 천자
- 덱사메타손 21- 포스페이트
- Deltacortene
- 프레드 닐리 덴
- N, N-Dicyclohexyl-Isoborneol-10-Sulfonamide
- Calaspargase Pegol
- 아자 티오 푸린
- 메르 포스
- 장막
- 덱사메타손 아세테이트
- 아스파라기나 제 Erwinia Chrysanthemi 재조합
- exifone
- Medrol Veriderm
기타 연구 ID 번호
- NCI-2024-01994
- U10CA180886 (미국 NIH 보조금/계약)
- NCI-2024-01994 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- AALL2321 (기타 식별자: CTEP)
- AALL2321 (기타 식별자: Children's Oncology Group)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .